10/ 539,483

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 3	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS 4	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 5	MAR 31	LPCI now available as a replacement to LDPCI
NEWS 6	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 7	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 8	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 9	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 10	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 11	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 12	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 13	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 14	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 15	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 16	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 17	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 18	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 19	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 20	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 21	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 22	JUL 28	CA/CAplus patent coverage enhanced
NEWS 23	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 24	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 25	JUL 28	STN Viewer performance improved
NEWS 26	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

```
 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:16:46 ON 05 AUG 2008

=> file reg
COST IN U.S. DOLLARS                                 SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                      0.21       0.21

FILE 'REGISTRY' ENTERED AT 17:17:11 ON 05 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    4 AUG 2008  HIGHEST RN 1038507-75-3
DICTIONARY FILE UPDATES:   4 AUG 2008  HIGHEST RN 1038507-75-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10539483.str
```





```
chain nodes :
11  12  14  15  18  19  20  21
ring nodes :
1  2  3  4  5  6  7  8  9  10
chain bonds :
2-18  7-11  11-12  14-15  18-19  19-20  20-21
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10
exact/norm bonds :
2-18  7-11  11-12  14-15  18-19  20-21
exact bonds :
19-20
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10
isolated ring systems :
containing 1 :


G1:O,S,N,SO2,[*1]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:CLASS  12:Atom  14:CLASS  15:CLASS  18:CLASS  19:CLASS  20:CLASS  21:CLASS
Element Count :
Node 12: Limited
    C,C5
    N,N1
```

L1 STRUCTURE UPLOADED

```
=> d L1
L1 HAS NO ANSWERS
L1                STR
```




```
G1 O,S,N,SO2,[@1]


Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 17:17:38 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      486 TO ITERATE

100.0% PROCESSED      486 ITERATIONS                                3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         8398 TO    11042
PROJECTED ANSWERS:               3 TO      163

L2            3 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 17:17:43 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     9633 TO ITERATE

100.0% PROCESSED     9633 ITERATIONS                               56 ANSWERS
SEARCH TIME: 00.00.01

L3           56 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                 178.36     178.57

FILE 'CAPLUS' ENTERED AT 17:17:48 ON 05 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 5 Aug 2008 VOL 149 ISS 6
FILE LAST UPDATED: 4 Aug 2008 (20080804/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l3
L4 3 L3

=> d l4 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:538808 CAPLUS
DOCUMENT NUMBER: 146:501078
TITLE: Preparation of 6-amino-4-(phenylamino)quinazoline derivatives as tyrosine kinase inhibitors
INVENTOR(S): Ahn, Young-Gil; Kim, Jong Woo; Bang, Keuk Chan; Park, Bum Woo; Kim, Se Young; Lee, Kyungik; Lee, Kyuhang; Ko, Myoung-Sil; Kim, Han Kyong; Kim, Young Hoon; Kim, Maeng Sup; Lee, Gwan Sun
PATENT ASSIGNEE(S): Hanmi Pharm. Co., Ltd., S. Korea
SOURCE: PCT Int. Appl., 217pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007055514	A1	20070518	WO 2006-KR4670	20061108

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

KR 2007049572 A 20070511 KR 2006-109137 20061106
KR 832594 B1 20080527
PRIORITY APPLN. INFO.: KR 2005-106506 A 20051108
KR 2006-109137 A 20061106
OTHER SOURCE(S): MARPAT 146:501078
GI



I

AB The title compds. [I; R1-R5 = independently H, HO, halogen, CF3, C1-6 alkyl, C1-6 alkoxy, C3-7 cycloalkyl, hydroxy-C1-5 alkyl, C1-6 alkoxy-C1-6 alkyl, NH2, amino-C1-4 alkyl, C1-6 alkylamino, C1-6 alkoxycarbonyl, C1-6 alkoxyaminocarbonyl, aryl-C1-6 alkoxy, heteroaryl-C1-6 alkoxy, or aryl; R6 = H, C1-6 alkyl or di(C1-6 alkyl)amino-C1-6 alkyl; X = (un)substituted C2-6 alkenylcarbonyl or C2-6 alkynylcarbonyl; Z = (un)substituted C1-6 alkoxy, C1-6 alkenyloxy, aryloxy, heterocyclyloxy, or heterocyclyl-C1-6 alkoxy] or pharmaceutically acceptable salts thereof are prepared These inventive quinazoline derivs. as multiplex inhibitors can selectively and effectively inhibit diseases caused by the overactivity of a tyrosine kinase, in particular a vascular endothelial growth factor receptor (VEGFR) or an epithelial cell growth factor receptor (EGFR). The diseases include cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, angioma, acute and chronic nephropathy, arterial restenosis, autoimmune disease, acute infection, and eye disease caused by vein abruption. These compds. effectively inhibited the growth of A431 having overexpressed EGFR1 (HER-1) and SK-Br3 having overexpressed EGFR2 (HER-2) at a low drug concentration, while the compds. did not inhibit the growth of SW-620 not having overexpressed EGFR and EGFR2. They also showed an excellent inhibitory effect on VEGFR-2 (KDR), which is an importance factor for inducing angiogenesis. Thus, amidation of 4-[6-amino-4-(4-bromo-2-fluorophenylamino)quinazolin-7-yloxymethyl]piperidine-1-carboxylic acid tert-Bu ester by acryloyl chloride in CH2Cl2 at room temperature for 2 h gave 4-[6-acryloylamino-4-(4-bromo-2-fluorophenylamino)quinazolin-7-yloxymethyl]piperidine-1-carboxylic acid tert-Bu ester which was deprotected by treatment with CF3CO2H in CH2Cl2 and acetylated by acetyl chloride in CH2Cl2 at room temperature for 2 h to give N-[7-(1-acetylpiperidin-4-ylmethoxy)-4-(4-bromo-2-fluorophenylamino)quinazolin-6-yl]acrylamide (II). II showed IC50 of 0.085, 0.048, 0.283, and 3.058 μM against HUVEC, A431, SKBr3, and SW-620 cancer cell lines, resp., and 0.131 and 0.003 μM against VEGFR-2 (KDR) and EGFR-1 (HER-1), resp.

IT 936558-91-7P, [2-[[4-[(6-Chloropyridin-3-yl)amino]-6-nitroquinazolin-7-yl]oxy]ethyl]carbamic acid tert-butyl ester 936558-92-8P, [7-(2-Aminoethoxy)-6-nitroquinazolin-4-yl](6-chloropyridin-3-yl)amine 936558-93-9P, N-[2-[[4-[(6-

Chloropyridin-3-yl)amino]-6-nitroquinazolin-7-yl]oxy]ethyl]acetamide
936558-94-0P, N-[2-[[6-Amino-4-[(6-chloropyridin-3-yl)amino]quinazolin-7-yl]oxy]ethyl]acetamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of 6-amino-4-(phenylamino)quinazoline derivs. as tyrosine kinase inhibitors)

RN 936558-91-7 CAPLUS
CN Carbamic acid, N-[2-[[4-[(6-chloro-3-pyridinyl)amino]-6-nitro-7-quinazolinyl]oxy]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 936558-92-8 CAPLUS
CN 4-Quinazolinamine, 7-(2-aminoethoxy)-N-(6-chloro-3-pyridinyl)-6-nitro- (CA INDEX NAME)



RN 936558-93-9 CAPLUS
CN Acetamide, N-[2-[[4-[(6-chloro-3-pyridinyl)amino]-6-nitro-7-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)



RN 936558-94-0 CAPLUS
CN Acetamide, N-[2-[[6-amino-4-[(6-chloro-3-pyridinyl)amino]-7-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)



IT 936558-89-3P, N-[7-(2-Acetylaminoethoxy)-4-[(6-chloropyridin-3-yl)amino]quinazolin-6-yl]acrylamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 6-amino-4-(phenylamino)quinazoline derivs. as tyrosine kinase inhibitors)
RN 936558-89-3 CAPLUS
CN 2-Propenamide, N-[7-[2-(acetylamino)ethoxy]-4-[(6-chloro-3-pyridinyl)amino]-6-quinazolinyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:566625 CAPLUS
DOCUMENT NUMBER: 141:123758
TITLE: Preparation of phosphonooxy quinazoline derivatives as therapeutic agents
INVENTOR(S): Mortlock, Andrew Austen
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Limited
SOURCE: PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058782	A1	20040715	WO 2003-GB5640	20031222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003294142	A1	20040722	AU 2003-294142	20031222
EP 1575966	A1	20050921	EP 2003-789562	20031222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006512387	T	20060413	JP 2004-563355	20031222
US 20060058325	A1	20060316	US 2005-539483	20050617
PRIORITY APPLN. INFO.:			EP 2002-293240	A 20021224
			WO 2003-GB5640	W 20031222

OTHER SOURCE(S): MARPAT 141:123758
GI



I

AB Preparation of phosphonooxy quinazoline derivs. I (A = 6-membered heteroaryl containing nitrogen atom and optionally containing one or two further nitrogen atoms; X = O, S, S(O), S(O)2, organoamino; m = 0-4; Y = O, carbonylamido, etc.; Z = organoamino, phosphonooxy, C3-6 (un)substituted phosphonooxy cycloalkyl, etc.; R3 = H, halo, cyano, nitro, C1-6 alkoxy, C1-6 alkyl, carbonylamido, sulfonylamido, organoamino, etc.; R4 = H, C1-4 alkyl, heteroaryl, heteroaryl C1-4 alkyl, aryl, aryl C1-4 alkyl, halo Me Et, cyclopropyl, ethynyl substituted alkyl, etc.), compns. containing them, processes for their preparation and their use in therapy, is described. Thus, reaction of N-{6-[(3-chlorobenzyl)oxy]pyridin-3-yl}-7-(3-chloropropoxy)-6-methoxyquinazolin-4-amine (preparation given) with 3-amino-3-methylbutanol in di-Me acetamide in the presence of KI gave 75% 3-[(3-{[4-({6-[(3-chlorobenzyl)oxy]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)amino]-3-methylbutan-1-ol which on treatment with di-tert-butyl-N,N-diethylphosphoramidite, oxidation with H2O2, and hydrolysis of the formed phosphate ester gave title compound, 3-[[3-[[4-[[6-[(3-chlorobenzyl)oxy]pyridin-3-yl]amino]-6-methoxyquinazolin-7-yl]oxy]propyl]amino]-3-methylbutyl dihydrogen phosphate.

IT 722485-20-3P 722485-21-4P 722485-22-5P
722485-26-9P 722485-27-0P 722485-30-5P
722485-32-7P 722485-34-9P 722485-36-1P
722485-37-2P 722485-39-4P 722485-46-3P
722485-48-5P 722485-71-4P 722485-75-8P
722485-83-8P 722485-97-4P 722486-05-7P
722486-28-4P 722486-37-5P 722486-43-3P
722486-52-4P 722486-59-1P 722486-65-9P
722486-85-3P 722486-93-3P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phosphonooxy quinazoline derivs. as therapeutic agents)

RN 722485-20-3 CAPLUS

CN 1-Butanol, 3-[[3-[[4-[[6-[(3-chlorophenyl)methoxy]-3-pyridinyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]-3-methyl-, dihydrogen phosphate (ester) (9CI) (CA INDEX NAME)



RN 722485-21-4 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[7-[3-[[1,1-dimethyl-3-(phosphonooxy)propyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyridinyl]- (CA INDEX NAME)



RN 722485-22-5 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[7-[3-[ethyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyridinyl]- (CA INDEX NAME)



RN 722485-26-9 CAPLUS
CN Benzamide, N-[5-[[7-[3-[ethyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyridinyl]-3-fluoro- (CA INDEX NAME)



RN 722485-27-0 CAPLUS
CN Benzamide, 3,4-difluoro-N-[5-[[6-methoxy-7-[3-[(1-methylethyl)[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-2-pyridinyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 722485-30-5 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[6-methoxy-7-[3-[methyl[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-2-pyridinyl]-(CA INDEX NAME)



RN 722485-32-7 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[7-[[5-[ethyl[2-(phosphonooxy)ethyl]amino]pentyl]oxy]-6-methoxy-4-quinazolinyl]amino]-2-pyridinyl]- (CA INDEX NAME)



RN 722485-34-9 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[7-[3-[ethyl[4-(phosphonooxy)butyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyridinyl]- (CA INDEX NAME)



RN 722485-36-1 CAPLUS
CN Benzamide, 3-fluoro-N-[5-[[6-methoxy-7-[3-[methyl[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-2-pyridinyl]-(CA INDEX NAME)



RN 722485-37-2 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[6-methoxy-7-[3-[(2-methylpropyl)[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-2-pyridinyl]-(CA INDEX NAME)



RN 722485-39-4 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[7-[3-[cyclopropyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyridinyl]- (CA INDEX NAME)



RN 722485-46-3 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[7-[3-[cyclobutyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyridinyl]- (CA INDEX NAME)



RN 722485-48-5 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[6-methoxy-7-[3-[[2-(phosphonooxy)ethyl]-2-propyn-1-ylamino]propoxy]-4-quinazolinyl]amino]-2-pyridinyl]- (CA INDEX NAME)



RN 722485-71-4 CAPLUS
CN 1-Butanol, 3-[[3-[[4-[[6-[(3-chlorophenyl)methoxy]-3-pyridinyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]-3-methyl-, dihydrogen phosphate (ester), dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

●2 HCl

RN 722485-75-8 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[7-[3-[[1,1-dimethyl-3-(phosphonooxy)propyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyridinyl]-, hydrochloride (1:3) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

●3 HCl

RN 722485-83-8 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[7-[3-[ethyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyridinyl]-, hydrochloride (1:3) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

●3 HCl

RN 722485-97-4 CAPLUS
CN Benzamide, N-[5-[[7-[3-[ethyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyridinyl]-3-fluoro-, hydrochloride (1:3) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

●3 HCl

RN 722486-05-7 CAPLUS
CN Benzamide, 3,4-difluoro-N-[5-[[6-methoxy-7-[3-[(1-methylethyl)[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-2-pyridinyl]-, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

● 2 HCl

RN 722486-28-4 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[6-methoxy-7-[3-[methyl[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-2-pyridinyl]-, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

●2 HCl

RN 722486-37-5 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[7-[[5-[ethyl[2-(phosphonooxy)ethyl]amino]pentyl]oxy]-6-methoxy-4-quinazolinyl]amino]-2-pyridinyl]-, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

●2 HCl

RN 722486-43-3 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[7-[3-[ethyl[4-(phosphonooxy)butyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyridinyl]-, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

●2 HCl

RN 722486-52-4 CAPLUS
CN Formic acid, compd. with 3-fluoro-N-[5-[[6-methoxy-7-[3-[methyl[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-2-pyridinyl]benzamide (1:1) (CA INDEX NAME)

CM 1

CRN 722485-36-1
CMF C27 H30 F N6 O7 P



CM 2

CRN 64-18-6
CMF C H2 O2

RN 722486-59-1 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[6-methoxy-7-[3-[(2-methylpropyl)[2-(phosphonooxy)ethyl]amino]propoxy]-4-quinazolinyl]amino]-2-pyridinyl]-, hydrochloride (1:2) (CA INDEX NAME)



RN 722486-65-9 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[7-[3-[cyclopropyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyridinyl]-, hydrochloride (1:2) (CA INDEX NAME)



RN 722486-85-3 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[7-[3-[cyclobutyl[2-(phosphonooxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyridinyl]-, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

●2 HCl

RN 722486-93-3 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[6-methoxy-7-[3-[[2-(phosphonooxy)ethyl]-2-propyn-1-ylamino]propoxy]-4-quinazolinyl]amino]-2-pyridinyl]-, hydrochloride (1:2) (CA INDEX NAME)



IT 722485-65-6P 722485-67-8P 722485-69-0P

722485-73-6P 722485-81-6P 722485-95-2P
722486-03-5P 722486-24-0P 722486-26-2P
722486-35-3P 722486-41-1P 722486-46-6P
722486-49-9P 722486-55-7P 722486-57-9P
722486-61-5P 722486-63-7P 722486-81-9P
722486-83-1P 722486-89-7P 722486-91-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phosphonooxy quinazoline derivs. as therapeutic agents)

RN 722485-65-6 CAPLUS
CN 1-Butanol, 3-[[3-[[4-[[6-[(3-chlorophenyl)methoxy]-3-pyridinyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]-3-methyl- (CA INDEX NAME)



RN 722485-67-8 CAPLUS
CN Phosphorous acid, 3-[[3-[[4-[[6-[(3-chlorophenyl)methoxy]-3-pyridinyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]-3-methylbutyl bis(1,1-dimethylethyl) ester (CA INDEX NAME)



RN 722485-69-0 CAPLUS
CN Phosphoric acid, 3-[[3-[[4-[[6-[(3-chlorophenyl)methoxy]-3-pyridinyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]-3-methylbutyl bis(1,1-dimethylethyl) ester (CA INDEX NAME)



RN 722485-73-6 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[7-[3-[(3-hydroxy-1,1-dimethylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyridinyl]- (CA INDEX NAME)



RN 722485-81-6 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyridinyl]- (CA INDEX NAME)



RN 722485-95-2 CAPLUS
CN Benzamide, N-[5-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyridinyl]-3-fluoro- (CA INDEX NAME)



RN 722486-03-5 CAPLUS
CN Benzamide, 3,4-difluoro-N-[5-[[7-[3-[(2-hydroxyethyl)(1-methylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyridinyl]- (CA INDEX NAME)

PAGE 1-A



F

RN 722486-24-0 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[7-[3-[(2-hydroxyethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyridinyl]- (CA INDEX NAME)



RN 722486-26-2 CAPLUS
CN Phosphoric acid, 2-[[3-[[4-[[6-[(3-chlorobenzoyl)amino]-3-pyridinyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]methylamino]ethyl bis(1,1-dimethylethyl) ester (CA INDEX NAME)



RN 722486-35-3 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[7-[[5-[ethyl(2-hydroxyethyl)amino]pentyl]oxy]-6-methoxy-4-quinazolinyl]amino]-2-pyridinyl]- (CA INDEX NAME)



RN 722486-41-1 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[7-[3-[ethyl(4-hydroxybutyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyridinyl]- (CA INDEX NAME)



RN 722486-46-6 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[7-[3-[ethyl[4-(phosphonooxy)butyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyridinyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 722485-34-9
CMF C30 H36 Cl N6 O7 P



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 722486-49-9 CAPLUS
CN Benzamide, 3-fluoro-N-[5-[[7-[3-[(2-hydroxyethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyridinyl]- (CA INDEX NAME)



RN 722486-55-7 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[7-[3-[(2-hydroxyethyl)(2-methylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyridinyl]- (CA INDEX NAME)



RN 722486-57-9 CAPLUS
CN Phosphoric acid, 2-[[3-[[4-[[6-[(3-chlorobenzoyl)amino]-3-pyridinyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl](2-methylpropyl)amino]ethyl bis(1,1-dimethylethyl) ester (CA INDEX NAME)

PAGE 1-A



RN 722486-61-5 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[7-[3-[cyclopropyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyridinyl]- (CA INDEX NAME)



RN 722486-63-7 CAPLUS
CN Phosphoric acid, 2-[[3-[[4-[[6-[(3-chlorobenzoyl)amino]-3-pyridinyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]cyclopropylamino]ethyl bis(1,1-dimethylethyl) ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 722486-81-9 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[7-[3-[cyclobutyl(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyridinyl]- (CA INDEX NAME)



RN 722486-83-1 CAPLUS
CN Phosphoric acid, 2-[[3-[[4-[[6-[(3-chlorobenzoyl)amino]-3-pyridinyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]cyclobutylamino]ethyl bis(1,1-dimethylethyl) ester (CA INDEX NAME)



RN 722486-89-7 CAPLUS
CN Benzamide, 3-chloro-N-[5-[[7-[3-[(2-hydroxyethyl)-2-propyn-1-ylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]-2-pyridinyl]- (CA INDEX NAME)



RN 722486-91-1 CAPLUS
CN Phosphoric acid, 2-[[3-[[4-[[6-[(3-chlorobenzoyl)amino]-3-pyridinyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-2-propyn-1-ylamino]ethyl bis(1,1-dimethylethyl) ester (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:228867 CAPLUS
DOCUMENT NUMBER: 134:266318
TITLE: Preparation of quinazolines as aurora 2 kinase inhibitors
INVENTOR(S): Mortlock, Andrew Austen; Keen, Nicholas John
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 208 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021597	A1	20010329	WO 2000-GB3593	20000919
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2384296	A1	20010329	CA 2000-2384296	20000919
BR 2000014137	A	20020521	BR 2000-14137	20000919
TR 200200717	T2	20020621	TR 2002-717	20000919
EP 1218355	A1	20020703	EP 2000-960850	20000919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003509500	T	20030311	JP 2001-524976	20000919
EE 200200118	A	20030415	EE 2002-118	20000919
HU 2003000205	A2	20030528	HU 2003-205	20000919
HU 2003000205	A3	20030828		
AU 762697	B2	20030703	AU 2000-73019	20000919
IN 2002MN00295	A	20050318	IN 2002-MN295	20020308
BG 106526	A	20021031	BG 2002-106526	20020318
ZA 2002002232	A	20030619	ZA 2002-2232	20020319
NO 2002001400	A	20020506	NO 2002-1400	20020320
US 7235559	B1	20070626	US 2002-88856	20020321
PRIORITY APPLN. INFO.:			GB 1999-22171 A	19990921
			WO 2000-GB3593 W	20000919

OTHER SOURCE(S): MARPAT 134:266318
GI



I



II

AB Title compds. (I) [wherein X = O, S, SO, SO2, NH, or NR6; R6 = H or alkyl; R5 = (un)substituted 6-membered aromatic ring containing at least one N; R1-R4 = independently halo, CN, NO2, alkylsulfanyl, N(OH)R7, or R9X1; R7 = H or alkyl; X1 = a direct bond, O, CH2, OC(O), CO, S, SO, SO2, or (un)substituted NHCO, CONH, SO2NH, NHSO2, or NH; R9 = H or (un)substituted hydrocarbyl, heterocyclyl, or alkoxy; and at least one of R2 or R3 is other than H; or a salt, ester, amide, or prodrug thereof] were prepared as aurora 2 kinase inhibitors for the treatment of proliferative diseases, such as cancer. For example, 2-(N-benzoylamino)-5-aminopyrimidine and 4-chloro-6,7-dimethoxyquinazoline were coupled in i-PrOH to yield II (58%). The latter inhibited the serine/threonine kinase activity of aurora 2 kinase by 50% at a concentration of 0.00785 μM. In addition, II gave 50% inhibition of MCF-7 cell proliferation at 1.7 μM and reduced BrdU incorporation into cellular DNA by 50% at 1.92-2.848 μM.

IT 331805-82-4P 331805-87-9P 331805-92-6P
331806-40-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compds.; preparation of substituted quinazoline derivs. as inhibitors of aurora 2 kinase for the treatment of breast and colorectal cancers)

RN 331805-82-4 CAPLUS

CN 4-Quinazolinamine, N-[6-[(3-chlorophenyl)methoxy]-3-pyridinyl]-6-methoxy-7-[3-[[3-(4-morpholinyl)propyl]amino]propoxy]- (CA INDEX NAME)



RN 331805-87-9 CAPLUS
CN 1,3-Propanediamine, N3-[3-[[4-[[6-[(3-chlorophenyl)methoxy]-3-pyridinyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-N1,N1-dimethyl- (CA INDEX NAME)



RN 331805-92-6 CAPLUS
CN Ethanol, 2-[[3-[[4-[[6-[(3-chlorophenyl)methoxy]-3-pyridinyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]methylamino]- (CA INDEX NAME)



RN 331806-40-7 CAPLUS
CN 1-Propanol, 2-[[3-[[4-[[6-[(3-chlorophenyl)methoxy]-3-pyridinyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]amino]-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

10/ 539,483

(FILE 'HOME' ENTERED AT 17:16:46 ON 05 AUG 2008)

FILE 'REGISTRY' ENTERED AT 17:17:11 ON 05 AUG 2008
L1 STRUCTURE UPLOADED
L2 3 S L1
L3 56 S L1 FULL

FILE 'CAPLUS' ENTERED AT 17:17:48 ON 05 AUG 2008
L4 3 S L3

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.83	195.40
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.40	-2.40

STN INTERNATIONAL LOGOFF AT 17:18:16 ON 05 AUG 2008